問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

Division of General Surgery

更新時間：2023-09-19

陳雅萍Chen, Ya-Ping
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

  • elinlcl206375@gmail.com

Recruiting Trial

117Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳雅萍

List

173Cases

2022-01-14 - 2026-07-31

Phase III

Active
xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2019-11-27 - 2022-03-31

Phase I/II

Completed
A Phase 1/2 Study of ASP2215 in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia

  • Condition/Disease

    Acute Myeloid Leukemia / FLT3-mutated Acute Myeloid Leukemia

  • Test Drug

    Gilteritinib (ASP2215)

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2022-06-30 - 2024-03-12

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-06-03 - 2031-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2019-09-01 - 2026-12-31

Phase II

Active
An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC) (KEYLYNK-009)

  • Condition/Disease

    Triple Negative Breast Neoplasms

  • Test Drug

    Pembrolizumab

Participate Sites
5Sites

Recruiting2Sites

Terminated3Sites

2023-11-01 - 2031-12-31

Phase III

Active
A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia who have an Inadequate Response to or are Intolerant of Hydroxyurea.

  • Condition/Disease

    Essential Thrombocythemia

  • Test Drug

    MK-3543

Participate Sites
5Sites

Recruiting5Sites

2023-10-15 - 2033-12-31

Phase III

Active
A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011)

  • Condition/Disease

    Chronic Lymphocytic Leukemia， Small Lymphocytic Lymphoma

  • Test Drug

    MK-1026MK-1026

Participate Sites
4Sites

Not yet recruiting2Sites

Recruiting2Sites

2024-11-20 - 2034-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2022-12-01 - 2031-12-31

Phase III

Active
A Phase 3, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Without TP53 Aberrations

  • Condition/Disease

    Chronic Lymphocytic Leukemia、Small Lymphocytic Lymphoma

  • Test Drug

    1026FludarabineCyclophosphamideMK-1026

Participate Sites
3Sites

Recruiting3Sites

2014-01-01 - 2021-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

1 3 4 5 6 7 18
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB